Lexeo Therapeutics Appoints Dr. Laura Sepp-Lorenzino to Board of Directors

On April 28, 2026, Lexeo Therapeutics, Inc. appointed Dr. Laura Sepp-Lorenzino to its Board of Directors. Dr. Sepp-Lorenzino will serve as a director until the 2028 Annual Meeting of Stockholders and has also been appointed to the Board's Science and Technology Committee. Dr. Sepp-Lorenzino brings extensive industry experience, having previously served as the Chief Scientific Officer of Intellia Therapeutics and holding senior roles at Vertex Pharmaceuticals, Alnylam Pharmaceuticals, and Merck & Co. In connection with her appointment, Dr. Sepp-Lorenzino will receive an annual cash retainer of $40,000, plus additional compensation for committee service. She was granted an initial stock option award for 50,000 shares of common stock upon her appointment. While she is eligible for annual equity grants under the company's Non-Employee Director Compensation Policy, she will not receive an annual grant for 2026 as her appointment date falls within six months of the 2026 annual meeting; she will first become eligible for the annual grant in 2027.